Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Capital Expenditures (2019 - 2024)

Black Diamond Therapeutics (BDTX) has disclosed Capital Expenditures for 3 consecutive years, with $333000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Capital Expenditures rose 134.51% year-over-year to $333000.0, compared with a TTM value of $2.7 million through Dec 2021, up 1808.45%, and an annual FY2023 reading of $33000.0, down 82.81% over the prior year.
  • Capital Expenditures was $333000.0 for Q4 2021 at Black Diamond Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.5 million in Q3 2021 and bottomed at -$2000.0 in Q2 2019.
  • Average Capital Expenditures over 3 years is $319222.2, with a median of $142000.0 recorded in 2020.
  • The sharpest move saw Capital Expenditures soared 7000.0% in 2020, then surged 134.51% in 2021.
  • Year by year, Capital Expenditures stood at $2000.0 in 2019, then skyrocketed by 7000.0% to $142000.0 in 2020, then soared by 134.51% to $333000.0 in 2021.
  • Business Quant data shows Capital Expenditures for BDTX at $333000.0 in Q4 2021, $1.5 million in Q3 2021, and $503000.0 in Q2 2021.